

In the Claims:

1. – 10 (Cancelled).

11. (Original) A method of inducing expression of FGF19 in a human hepatocyte cell, comprising administering an FXR agonist to said cell.

12. (Original) A method according to claim 11, wherein said FXR agonist is selected from the group consisting of GW4064; $3\alpha,7\alpha$ -dihydroxy- 6α -ethyl- 5β -cholan-24-oic acid; $3\alpha,7\alpha$ -dihydroxy- 6α -propyl- 5β -cholan-24-oic acid; and $3\alpha,7\alpha$ -dihydroxy- 6α -allyl- 5β -cholan-24-oic acid, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.

13. (Original) A method according to claim 11 where said cell is *in vitro*.

14. – 19. (Cancelled).